Gagnon Robert E., the Chief Financial Officer of Opus Genetics, Inc., has sold 14,000 shares of the company's stock. This transaction, reported in a recent SEC filing, is part of a pre-arranged trading plan established earlier this year.

The sale took place on October 23, 2026, at a weighted average price of $3.5464 per share. According to the filing, the shares were sold to cover tax withholding obligations related to the vesting and settlement of restricted stock units. It is important to note that this transaction does not represent a discretionary trade by Gagnon, as it was executed under a Rule 10b5-1 trading plan.

Background

Opus Genetics, Inc., identified by the CIK 0001228627, operates within the pharmaceutical preparations sector. The company is incorporated in Delaware and has its business address in Durham, North Carolina. Opus Genetics focuses on innovative solutions in the life sciences field and is publicly traded under the ticker symbol IRD.

What the Filing Says

The SEC filing, accession number 0001140361-26-040896, indicates that Gagnon sold the shares to manage tax obligations associated with his compensation. The filing states, "The shares reported on this line were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 30, 2026." This plan allows for automatic sales based on a predetermined formula, ensuring compliance with regulations while managing personal tax liabilities.

Impact

This sale may affect various stakeholders, including investors and analysts monitoring Opus Genetics' stock performance. Gagnon retains a significant ownership stake, with 542,375 shares remaining after the transaction. The move could influence investor sentiment and market perceptions of the company's financial health, particularly in the competitive landscape of pharmaceutical preparations.

What's Next

The filing does not say what happens next.